Gilead will supply the drug, while BioNTech will continue to sponsor and lead ROSETTA Breast-01. The proposed protocol change requires regulatory approval.
BioNTech Plans Trodelvy Combination in Global Phase 3 Breast Cancer Trial
Gilead will supply the drug, while BioNTech will continue to sponsor and lead ROSETTA Breast-01. The proposed protocol change requires regulatory approval.